Viking Therapeutics is advancing its lead candidate VK2735, a GLP-1 dual agonist for weight management, into Phase 3 studies after delivering robust Phase 2 data showing double-digit percentage reductions in body weight versus placebo. Study completion is expected in mid-2026, with topline results due by Q3. The company is also developing an oral formulation of VK2735; although high doses in Phase 2 triggered elevated dropout rates due to gastrointestinal adverse events, lower doses achieved comparable efficacy with improved tolerability. Positive Phase 3 outcomes could position Viking for regulatory filings in 2027 and capture a share of the fast-growing anti-obesity market, which is projected to exceed $40 billion globally by 2030.

Viking Therapeutics benefits from strong institutional backing, with approximately 76 percent of shares held by institutional investors, a level well above peer averages for clinical-stage biotechs. Insider ownership stands at 4.1 percent, aligning management incentives with shareholder value. The company reported a net loss of $110 million in the latest fiscal year, narrowing from the prior year’s $135 million deficit, as R&D expenses scaled with Phase 3 trial investments. Viking ended Q4 with $250 million in cash and equivalents, providing runway into late 2027. Analysts maintain a consensus ‘Moderate Buy’ rating, citing the potential for significant upside upon positive pivotal data and subsequent deal interest from larger pharmaceutical partners.